BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) is gearing up for significant investor engagement this September. The company’s management will meet with investors at the Wells Fargo Healthcare Conference in Boston from September 4-6 and at the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9-11.
These conferences present crucial opportunities for Larimar to discuss its pipeline and strategic direction. As a clinical-stage biotech firm, Larimar focuses on tackling complex rare diseases. Its lead compound, nomlabofusp, is being developed to treat Friedreich’s ataxia. The company also aims to create additional therapies using its innovative intracellular delivery platform, targeting rare diseases linked to intracellular deficiencies. These meetings are a pivotal step for Larimar in strengthening investor relations and highlighting its progress in rare disease treatment development.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.